Longboard Pharmaceuticals Inc
NASDAQ:LBPH
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
N/A
N/A
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Longboard Pharmaceuticals Inc
EPS (Diluted)
Longboard Pharmaceuticals Inc
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Longboard Pharmaceuticals Inc
NASDAQ:LBPH
|
EPS (Diluted)
-$1
|
CAGR 3-Years
-4%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
EPS (Diluted)
$10
|
CAGR 3-Years
13%
|
CAGR 5-Years
10%
|
CAGR 10-Years
7%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
EPS (Diluted)
$2
|
CAGR 3-Years
-2%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
11%
|
|
|
Pfizer Inc
NYSE:PFE
|
EPS (Diluted)
$1
|
CAGR 3-Years
-31%
|
CAGR 5-Years
4%
|
CAGR 10-Years
3%
|
|
|
Merck & Co Inc
NYSE:MRK
|
EPS (Diluted)
$7
|
CAGR 3-Years
8%
|
CAGR 5-Years
12%
|
CAGR 10-Years
7%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
EPS (Diluted)
$20
|
CAGR 3-Years
45%
|
CAGR 5-Years
27%
|
CAGR 10-Years
25%
|
|
Longboard Pharmaceuticals Inc
Glance View
Nestled in the bustling biotech landscape, Longboard Pharmaceuticals Inc. has carved its niche by steering its focus toward developing transformative therapies for neurological diseases. Born from the strategic insights honed within Arena Pharmaceuticals, Longboard carries forward an unwavering commitment to unraveling the complexities of neurobiology. At its core, the company's research is laser-focused on advancing a robust pipeline, notably targeting conditions with high unmet needs such as epilepsy and other neuropsychiatric disorders. The cornerstone of their approach lies in leveraging cutting-edge science to target specific neurological pathways, thus fostering innovative drug candidates that hold the potential to redefine treatment paradigms. The financial engine of Longboard turns primarily on its potential to bring successful therapies to market. Like many firms in the biotech sector, its journey from the lab bench to patient bedside is fraught with substantial R&D investments, clinical trial navigation, and regulatory hurdles. The promise of substantial returns hinges on achieving significant breakthroughs, securing FDA approval, and eventually commercializing their therapies. Additional revenue streams might emerge through strategic partnerships, collaborations, and licensing agreements with other pharmaceutical entities, which can provide both immediate funding and shared resources to propel their products forward. Ultimately, Longboard’s financial health is intertwined with its scientific progress and regulatory milestones, painting a picture of a company deeply embedded in the rhythms of innovation and impact-driven healthcare solutions.
See Also
What is Longboard Pharmaceuticals Inc's EPS (Diluted)?
EPS (Diluted)
-2
USD
Based on the financial report for Sep 30, 2024, Longboard Pharmaceuticals Inc's EPS (Diluted) amounts to -2 USD.
What is Longboard Pharmaceuticals Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 3Y
-4%
Over the last year, the EPS (Diluted) growth was 10%. The average annual EPS (Diluted) growth rates for Longboard Pharmaceuticals Inc have been -4% over the past three years .